첨단 약물전달 CDMO : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the advanced drug delivery cDMO market is expected to grow from USD 7.64 billion in 2025 to USD 8.96 billion in 2026 and is forecasted to reach USD 21.06 billion by 2031 at 18.64% CAGR over 2026-2031.

This report is Segmented by Drug Delivery Technology (Nanoparticle-Based Delivery and More), Service Type (Pre-Formulation & Formulation Development and More), Molecule Type (Small Molecules and More), Therapeutic Area (Oncology and More), Client Type (Pharmaceutical and Biotechnology Company and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Advanced Drug Delivery CDMO Market Trends and Insights

Increase in Demand for Complex Biologics

Blockbuster antibody patent expiries, coupled with sponsor reluctance to fund USD 300 million mammalian-cell suites, are pushing projects to CDMOs. FUJIFILM Diosynth secured a USD 3 billion, ten-year manufacturing pact with Regeneron in April 2025, the largest single CDMO contract to date. Samsung Biologics booked USD 3.3 billion in new deals in 1H 2025, underscoring the appeal of mega-contracts that guarantee multi-year slots. Regulators have now cleared more than 70 biosimilars in the United States, creating a supply rush that favors CDMOs holding validated cell-culture and aseptic suites.

Outsourcing to Accelerate Time-to-Market

Integrated API-to-drug-product models cut the interval from pre-clinical handoff to first-in-human dosing by roughly 40%, giving venture-backed firms earlier revenue recognition. Pfizer's CentreOne unit reported that clients leveraging its end-to-end capability filed INDs six months sooner than those coordinating multiple vendors. United States and EU regulators now offer joint advice on novel delivery platforms, reducing review uncertainty and tilting sponsor preference toward CDMOs with proven regulatory track records. Single-use, modular bioreactor farms, such as FUJIFILM's KojoX network, allow CDMOs to spin up clinical batches in weeks, accelerating program starts while commercial talks proceed in parallel.

High Capital Expenditure & Validation Costs

Building a single commercial line for antibody-drug conjugates can top USD 200 million, with validation adding another USD 20 million before launch. Lonza's CHF 500 million Ibex Dedicate ADC hub and Samsung's USD 2.1 billion Bio Campus IV exemplify the financial hurdle. Multi-product plants face doubled timelines because introducing a second biologic necessitates new cleaning studies and residue testing per FDA guidance. Debt markets in 2025 priced CDMO loans 250 basis points over benchmark rates, reflecting lender caution around technology obsolescence.

Other drivers and restraints analyzed in the detailed report include:

1. Growth in Injectable and Controlled-Release Formats
2. Regulatory Incentives for Advanced Therapies
3. Stringent Multi-region Compliance Audits

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Nanoparticle formats held 37.90% of 2025 revenue, cementing their role as the backbone of the Advanced Drug Delivery CDMO market. The lipid nanoparticle toolkit that enabled COVID-19 mRNA vaccines now underpins oncology and rare-disease programs, pushing demand for sterile microfluidics and high-shear mixers. Liposomal and broader lipid-based systems are forecast to post the fastest 19.42% CAGR through 2031. This momentum rests on prolonged circulation times and superior end-organ accumulation, which trim systemic toxicity. Long-acting injectables built on PLGA microspheres captured a meaningful share by delivering stable plasma levels for up to six months, addressing adherence gaps in schizophrenia and HIV prophylaxis. Transdermal and microneedle innovations cater to needle-averse cohorts, while controlled-release oral platforms continue to dominate chronic disease management. CDMOs that house parallel nanoparticle, liposome, and depot lines are winning cross-modality contracts that preserve sponsor optionality over the molecule's life cycle.

Analytical and characterization, the fastest-growing segment at 19.21% through 2031, secure their lift from the global pivot toward ready-to-inject formats. Aseptic isolators that meet ISO Class 5 norms command premium pricing, especially for high-viscosity biologics. Pre-formulation labs that use in silico models reduce downstream rework, and bundled analytical packages meet real-time release and ICH Q12 continuous-verification requirements. Patient-specific labeling and serialization services generate incremental revenue by solving last-mile clinical-trial logistics challenges.

Geography Analysis

North America delivered 43.25% of global revenue in 2025. FDA-inspected facilities near Boston, San-Francisco, and San Diego clusters offer expedited review under Breakthrough and RMAT designations. The United States has the world's most significant fill-finish footprint, yet utilization exceeded 85% in 2024, inflating slot prices and lead times. Canada extends 35% R&D tax credits, while Mexico's proximity lures sterile injectable manufacturing despite dual FDA-COFEPRIS oversight.

Europe retains a solid share on the back of the EMA's centralized approval, with Switzerland, Germany, and the United Kingdom housing advanced biologic suites. The UK's ILAP shortens time-to-market, attracting WuXi and Samsung Biologics to add GMP floor space. Italy and Spain scale biosimilar output to meet Southern Europe and MENA demand, though infrastructure lags Northern Europe by 5 years.

Asia-Pacific is the fastest-growing region, with 21.03% growth through 2031. China's 2024 policy reduced biologic approval timelines to 12 months, prompting multinationals to include Chinese CDMOs in their global supply chains. India's Biocon and Piramal expanded peptide and biosimilar capacity to serve cost-sensitive geographies. Australia's mutual-recognition pact with the EMA lets European-approved products enter on abbreviated review, enabling Oceania supply from EU plants. Latin America remains mixed; Argentina's currency swings deter new builds, but existing GMP sites tap regional rare-disease trials.

1. Ajinomoto Bio-Pharma Services
2. Alcami
3. Baxter
4. Delpharm
5. Emergent
6. Evonik Health Care
7. Fareva
8. Jubilant HollisterStier
9. Lonza Group
10. PCI Pharma Services
11. Piramal Group
12. Recipharm
13. Samsung Group
14. Siegfried Holding AG
15. SK pharmteco
16. Thermo Fisher Scientific Inc. (Patheon)
17. Vetter Pharma
18. WuXi STA (WuXi AppTec)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increase in Demand for Complex Biologics
  • 4.2.2 Outsourcing to Accelerate Time-to-Market
  • 4.2.3 Growth in Injectable and Controlled-Release Formats
  • 4.2.4 Regulatory Incentives for Advanced Therapies
  • 4.2.5 Micro-Batch Capacity for High-Potency Drugs
  • 4.2.6 3D-Printed Implantable Delivery Systems
• 4.3 Market Restraints
  • 4.3.1 High Capital Expenditure & Validation Costs
  • 4.3.2 Stringent Multi-region Compliance Audits
  • 4.3.3 Excipients Supply-chain Bottlenecks
  • 4.3.4 Shortage of skilled professionals in nano-encapsulation
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Delivery Technology
  • 5.1.1 Nanoparticle-based Delivery
  • 5.1.2 Liposomal / Lipid-based Delivery
  • 5.1.3 Long-acting Injectables
  • 5.1.4 Implantable Delivery Systems
  • 5.1.5 Transdermal Patches & Microneedles
  • 5.1.6 Oral Controlled-Release Systems
  • 5.1.7 Other Advanced Delivery Technology
• 5.2 By Service Type
  • 5.2.1 Pre-formulation & Formulation Development
  • 5.2.2 Analytical & Characterization Services
  • 5.2.3 Scale-up & Process Development
  • 5.2.4 Clinical & Commercial Manufacturing
  • 5.2.5 Fill -finish & Aseptic Processing
  • 5.2.6 Packaging & Kitting
  • 5.2.7 Others Service Type
• 5.3 By Molecule Type
  • 5.3.1 Small Molecules
  • 5.3.2 Biologics & Biosimilars
  • 5.3.3 Gene & Cell Therapies
  • 5.3.4 Peptide & Oligonucleotide Therapeutics
• 5.4 By Therapeutic Area
  • 5.4.1 Oncology
  • 5.4.2 Central Nervous System Disorders
  • 5.4.3 Infectious Diseases & Vaccines
  • 5.4.4 Cardiovascular & Metabolic Disorders
  • 5.4.5 Rare Diseases & Orphan Indications
  • 5.4.6 Other Therapeutic Areas
• 5.5 By Client Type
  • 5.5.1 Pharmaceutical and Biotechnology Company
  • 5.5.2 Academic and Government Institutions
  • 5.5.3 Others Client Type
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 France
    • 5.6.2.3 United Kingdom
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Ajinomoto Bio-Pharma Services
  • 6.3.2 Alcami Corporation
  • 6.3.3 Baxter
  • 6.3.4 Delpharm
  • 6.3.5 Emergent
  • 6.3.6 Evonik Health Care
  • 6.3.7 Fareva
  • 6.3.8 Jubilant HollisterStier
  • 6.3.9 Lonza Group AG
  • 6.3.10 PCI Pharma Services
  • 6.3.11 Piramal Pharma Solutions
  • 6.3.12 Recipharm AB
  • 6.3.13 Samsung Biologics
  • 6.3.14 Siegfried Holding AG
  • 6.3.15 SK pharmteco
  • 6.3.16 Thermo Fisher Scientific Inc. (Patheon)
  • 6.3.17 Vetter Pharma
  • 6.3.18 WuXi STA (WuXi AppTec)

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment